The influence of folate pathway polymorphisms on high-dose methotrexaterelated toxicity and survival in children with non-Hodgkin malignant lymphoma

Radiology and Oncology

Volumn 48, Issue 3, 2014, Pages 289-292

  Erculj, Nina ^a   Kotnik, Barbara Faganel ^b   Debeljak, Marusa ^b   Jazbec, Janez ^b   Dolzan, Vita ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

Author keywords

Childhood; Folate pathway; High dose methotrexate; Non Hodgkin lymphoma; Polymorphism; Toxicity

Indexed keywords

FOLIC ACID; GENOMIC DNA; METHOTREXATE;

ALLELE; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; DNA POLYMORPHISM; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; GENOTYPE; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; T CELL LYMPHOMA; THROMBOCYTOPENIA; WILD TYPE;

EID: 84929141846     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/raon-2013-0076     Document Type: Article

References (9)

1. Gregoric B, Zadnik V, Jezersek Novakovic B. The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice. Radiol Oncol 2012;46:153-9.
2. Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000;95:416-21.
3. Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dolzan V, Jazbec J. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 2011;67:993-1006.
4. Erculj N, Kotnik BF, Debeljak M, Jazbec J, Dolzan V. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia. Leuk Lymphoma 2012;53:1096-104.
5. Jazbec J, Kitanovski L, Aplenc R, Debeljak M, Dolzan V. No evidence of association of methylenetetrahydrofolate reductase polymorphism with occurrence of second neoplasms after treatment of childhood leukemia. Leuk Lymphoma 2005;46:893-7.
6. Petra BG, Janez J, Vita D. Gene-gene interactions in the folate metabolic pathway influence the risk for acute lymphoblastic leukemia in children. Leuk Lymphoma 2007;48:786-92.
7. Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 2007;52:166-71.
8. Kantar M, Kosova B, Cetingul N, Gumus S, Toroslu E, Zafer N, et al. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:912-7.
9. Seidemann K, Book M, Zimmermann M, Meyer U, Welte K, Stanulla M, et al. MTHFR 677 (C→T) polymorphism is not relevant for prognosis or therapyassociated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95. Ann Hematol 2006;85:291-300.